Table 2.
Results of direct comparsions
| Outcome | Treatment | No. of studies |
No. of patients |
HR/OR(95%CI) | Heterogeneity | |
|---|---|---|---|---|---|---|
| I2(%) | P | |||||
| OS | nCRTS-ENI vs S alone | 6 | 432 | HR 0.70(0.54–0.92) | 8 | 0.37 |
| nCRTS-IFI vs S alone | 10 | 2228 | HR 0.74(0.66–0.83) | 10 | 0.35 | |
| nCTS vs S alone | 13 | 2526 | HR 0.86(0.76–0.98) | 40 | 0.06 | |
| LR | nCRTS-ENI vs S alone | 4 | 288 | OR 0.69(0.35–1.35) | 46 | 0.13 |
| nCRTS-IFI vs S alone | 6 | 1221 | OR 0.43(0.33–0.57) | 0 | 0.50 | |
| nCTS vs S alone | 7 | 2176 | OR 0.79(0.62–0.99) | 26 | 0.23 | |
| DM | nCRTS-ENI vs S alone | 4 | 288 | OR 0.87(0.35–2.21) | 57 | 0.07 |
| nCRTS-IFI vs S alone | 6 | 1221 | OR 0.79(0.62–1.00) | 0 | 0.43 | |
| nCTS vs S alone | 7 | 2176 | OR 0.83(0.68–1.01) | 37 | 0.15 | |
| R0 resection | nCRTS-ENI vs S alone | 2 | 155 | OR 5.75(2.19–15.13) | 0 | 0.61 |
| nCRTS-IFI vs S alone | 4 | 1119 | OR 5.17(1.95–13.67) | 68 | 0.02 | |
| nCTS vs S alone | 7 | 1705 | OR 1.71(1.39–2.10) | 0 | 0.75 | |
| nCRTS-ENI vs nCT | 2 | 166 | OR 4.71(1.98–11.24) | 0 | 0.85 | |
| POM | nCRTS-ENI vs S alone | 5 | 324 | OR 1.52(0.66–3.52) | 0 | 0.85 |
| nCRTS-IFI vs S alone | 8 | 1704 | OR 1.79(1.14–2.82) | 27 | 0.21 | |
| nCTS vs S alone | 11 | 2453 | OR 1.02(0.75–1.38) | 0 | 0.87 | |
Abbreviations: No. Number, HR Hazard ratio, CI Confidence interval, OR Odds ratio, OS Overall survival, LR Locoregional recurrence, DM Distant metastases, POM Post-operative mortality, nCRTS Neoadjuvant chemoradiotherapy plus surgery, nCTS Neoadjuvant chemotherapy plus surgery, S Surgery, ENI Elective nodal irradiation, IFI Involved-field irradiation
Significant results are in bold